To determine the diagnostic value of preoperative inflammatory biomarkers and CA199, alone or in combination, in diagnosing pancreatic cancer (PCC).
This retrospective study was comprised of 75 PCC patients and 83 healthy controls (HC). The participant’s medical data was mined from the electronic records of the First Affiliated Hospital of Guangxi Medical University. The data included the preoperative circulating albumin/fibrinogen ratio (AFR), the platelet/lymphocyte ratio (PLR), the lymphocyte/monocyte ratio (LMR), the neutrophil/lymphocyte ratio (NLR), and the derived NLR (dNLR). The receiver operating characteristic (ROC) curve and the area under the ROC curve (AUROC) were used to evaluate the diagnostic efficacy of these candidate biomarkers for PCC.
A single AFR significantly distinguished PCC from the healthy controls (AUROC: 0.903, 95% CI: 0.846 – 0.945) and had a significantly higher sensitivity and larger AUROC than CA199 (AUROC: 0.814, 95% CI: 0.774 – 0.871). The combinations of AFR with CA199 (AUROC: 0.932, 95% CI: 0.881 – 0.966), RDW with CA199 (AUROC: 0.905, 95% CI: 0.849 – 0.946), Alb with CA199 (AUROC: 0.869, 95% CI: 0.806 – 0.917), and Fib with CA199 (AUROC: 0.921, 95% CI: 0.868 – 0.958) also yielded higher sensitivities and larger AUROCs than CA199 alone.
Circulating AFR was an effective biomarker in diagnosing PCC. Combining AFR, RDW, Alb, and Fib with CA199 could improve the diagnostic efficacy for PCC.